International Clinical Psychopharmacology

Aims & Scope

International Clinical Psychopharmacology provides an essential link between research and clinical practice throughout psychopharmacology.

It reports on studies in human subjects, both healthy volunteers and patients, which relate the effects of drugs on psychological processes.

A major objective of the journal is to publish fully refereed papers which throw light on the ways in which the study of psychotropic drugs can increase our understanding of psychopharmacology.

To this end the journal publishes results of early Phase I and II studies, as well as those of controlled clinical trials of psychotropic drugs in Phase II and IV.

Other topics covered include the epidemiology of psychotropic drug prescribing and drug taking, the sociology of psychotropic drugs including compliance, and research into the safety and adverse effects of these compounds.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	2.5
2024	2.10

SJR (SCImago Journal Rank)

Year	Value
2024	0.642

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	100

Journal Rank

Year	Value
2024	8987

Journal Citation Indicator

Year	Value
2024	314

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• The measurement of disability

  Citation: 1083

  Authors: D V, K, B A

• Efficacy of treatments for anxiety disorders

  Citation: 444

  Authors: Borwin, Markus, Christian, Sophie, Yvonne, Dirk

• Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale

  Citation: 361

  Authors: Kathy Harnett, David V.

• Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)

  Citation: 358

  Authors: J.

• Depression in the community

  Citation: 343

  Authors: J. -P., M., J., A.

• The social and economic burden of treatment-resistant schizophrenia

  Citation: 337

  Authors: James L., C. Anthony, Danielle L., Irina, John C.

• A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

  Citation: 335

  Authors: Cornelius, Thomas, Christina Kurre

• Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

  Citation: 287

  Authors: H., A., H.

• Antioxidant enzyme activities and oxidative stress in affective disorders

  Citation: 286

  Authors: M., Mukaddes, Elif, Ruhcan, Omer

• Imputing response rates from means and standard deviations in meta-analyses

  Citation: 277

  Authors: Toshi A., Andrea, Corrado, Paolo, Norio

---